Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in wild type, accelerating drug discovery for sporadic neurodegenerative diseases.


SynAging will be present at the following meetings in 2018:

Neuro4D Meeting June 4-5, Mainz, Germany

AAIC Meeting July 22-26, Chicago, USA

Society for Neuroscience Meeting November 3-7, San Diego, USA

SynAging' past meetings in 2017:

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt Main, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies Meeting in Athens, September 7-10, 2017

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings:

Press & Publications

SynAging's Poster won the 'Best Poster Award' here during the '20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies' meeting in Athens, September 7-10, 2017 entitled:
Download PDF

Download PDF

Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance;  Link

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease

Download PDF

Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF



Publications on the application of SynAging’s AD model:

Antonios G, 1†, Saiepour N, Bouter Y, Richard BC, Paetau A, Verkkoniemi-Ahola A, Lannfelt L, Ingelsson L, Kovacs GG, Pillot T, Wirths O, Bayer TA. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. A. NeuropathologicaCom.. 2013, 1:56

Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA. N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. ActaNeuropathol. 2013 Aug; 126(2):189-205. doi: 10.1007/s00401-013-1129-2. Epub 2013 May 18. PubMed PMID: 23685882; PubMed Central PMCID: PMC3722453.

Desbène C, Malaplate-Armand C, Youssef I, Garcia P, Stenger C, Sauvée M, Fischer N, Rimet D, Koziel V, Escanyé MC, Oster T, Kriem B, Yen FT, Pillot T, Olivier JL. Critical role of cPLA(2) in Aβ oligomer-induced neurodegeneration and memory deficit. Neurobiol.Aging. 2012 Jun;33(6):1123.e17-29

Stenger C, Pinçon A, Hanse M, Royer L, Comte A, Koziel V, Olivier JL, Pillot T, Yen FT. Brain region-specific immunolocalization of the lipolysis-stimulated lipoprotein receptor (LSR) and altered cholesterol distribution in aged LSR(+/-) mice. J. Neurochem. 2012 Nov;123(4):467-76

Oster T, Pillot T. Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochim.Biophys.Acta. 2010 Aug;1801(8):791-8.

Florent-Béchard S, Desbène C, Garcia P, Allouche A, Youssef I, Escanyé MC, Koziel V, Hanse M, Malaplate-Armand C, Stenger C, Kriem B, Yen-Potin FT, Olivier JL, Pillot T, Oster T. The essential role of lipids in Alzheimer's disease.Biochimie. 2009 Jun;91(6):804-9.

Malaplate-Armand C, Desbene C, Pillot T, Olivier JL. [Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions]. Rev Neurol(Paris). 2009 Jun-Jul;165(6-7):511-20.

Abildayeva K, Berbée JF, Blokland A, Jansen PJ, Hoek FJ, Meijer O, Lütjohann D, Gautier T, Pillot T, De Vente J, Havekes LM, Ramaekers FC, Kuipers F, Rensen PC, Mulder M. Human apolipoprotein C-I expression in mice impairs learning and memory functions. J. Lipid Res. 2008 Apr;49(4):856-69.

Florent-Béchard S, Malaplate-Armand C, Koziel V, Kriem B, Olivier JL, Pillot T, Oster T. Towards a nutritional approach for prevention of Alzheimer's disease: biochemical and cellular aspects. J. Neurol. Sci. 2007 Nov 15;262(1-2):27-36.


Publications of SynAging’s AD model:

Garcia P, Youssef I, Utvik JK, Florent-Béchard S, Barthélémy V, Malaplate-Armand C, Kriem B, Stenger C, Koziel V, Olivier JL, Escanye MC, Hanse M, Allouche A, Desbène C, Yen FT, Bjerkvig R, Oster T, Niclou SP, Pillot T. Ciliaryneurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J. Neurosci. 2010 Jun 2;30(22):7516-27.

Youssef I, Florent-Béchard S, Malaplate-Armand C, Koziel V, Bihain B, Olivier JL, Leininger-Muller B, Kriem B, Oster T, Pillot T. N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. Neurobiol.Aging. 2008 Sep;29(9):1319-33.


Publications on the mode of toxicity of soluble oligomers in SynAging’s AD model:

Malaplate-Armand C, Florent-Béchard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 2006 Jul;23(1):178-89.

Florent S, Malaplate-Armand C, Youssef I, Kriem B, Koziel V, Escanyé MC, Fifre A, Sponne I, Leininger-Muller B, Olivier JL, Pillot T, Oster T. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J. Neurochem. 2006 Jan;96(2):385-95.

Fifre A, Sponne I, Koziel V, Kriem B, Yen Potin FT, Bihain BE, Olivier JL, Oster T, Pillot T. Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3.J. Biol. Chem. 2006 Jan 6;281(1):229-40.

Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac'h-Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, Pillot T. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J. 2005 Jan;19(1):85-7.

Sponne I, Fifre A, Koziel V, Kriem B, Oster T, Olivier JL, Pillot T. Oligodendrocytes are susceptible to apoptotic cell death induced by prion protein-derived peptides. Glia. 2004 Jul;47(1):1-8.

Sponne I, Fifre A, Koziel V, Oster T, Olivier JL, Pillot T. Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of amyloid-beta peptide. FASEB J. 2004 May;18(7):836-8.

Sponne I, Fifre A, Koziel V, Kriem B, Oster T, Pillot T. Humanin rescues cortical neurons from prion-peptide-induced apoptosis. Mol. Cell. Neurosci.2004 Jan;25(1):95-102.

Morel E, Fouquet S, Chateau D, Yvernault L, Frobert Y, Pincon-Raymond M, Chambaz J, Pillot T, Rousset M. The cellular prion protein PrPc is expressed in human enterocytes in cell-cell junctional domains. J. Biol. Chem. 2004 Jan 9;279(2):1499-505.

Klein C, Pillot T, Chambaz J, Drouet B. Determination of plasma membrane fluidity with a fluorescent analogue of sphingomyelin by FRAP measurement using a standard confocal microscope. Brain Res. Protoc. 2003 Mar;11(1):46-51.

Chabry J, Ratsimanohatra C, Sponne I, Elena PP, Vincent JP, Pillot T. In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression. J. Neurosci. 2003 Jan 15;23(2):462-9.

Sponne I, Fifre A, Drouet B, Klein C, Koziel V, Pinçon-Raymond M, Olivier JL, Chambaz J, Pillot T. Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem. 2003 Jan 31;278(5):3437-45.

Bossenmeyer-Pourié C, Lièvre V, Grojean S, Koziel V, Pillot T, Daval JL. Sequential expression patterns of apoptosis- and cell cycle-related proteins in neuronal response to severe or mild transient hypoxia. Neuroscience. 2002;114(4):869-82.

Anello G, Guéant J, Romano C, Barone C, Pettinato R, Pillot T, Rodriguez R, Romano A, Bosco P. Allele varepsilon4 of apolipoprotein E gene is less frequent in Down syndrome patient of the Sicilian population and has no influence on the grade of mental retardation. Neurosci .Lett. 2001 Jun 22;306(1-2):129-31.

Drouet B, Fifre A, Pinçon-Raymond M, Vandekerckhove J, Rosseneu M, Guéant JL, Chambaz J, Pillot T. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J. Neurochem. 2001 Jan;76(1):117-27.

Pillot T, Drouet B, Pinçon-Raymond M, Vandekerckhove J, Rosseneu M, Chambaz J. A nonfibrillar form of the fusogenic prion protein fragment [118-135] induces apoptotic cell death in rat cortical neurons. J. Neurochem. 2000 Dec;75(6):2298-308.

Drouet B, Pinçon-Raymond M, Chambaz J, Pillot T. Molecular basis of Alzheimer's disease. Cell. Mol. Life Sci. 2000 May;57(5):705-15.

Pillot T, Drouet B, Queillé S, Labeur C, Vandekerchkhove J, Rosseneu M, Pinçon-Raymond M, Chambaz J. The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. J. Neurochem. 1999 Oct;73(4):1626-34.

Lins L, Thomas-Soumarmon A, Pillot T, Vandekerchkhove J, Rosseneu M, Brasseur R. Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices. J. Neurochem. 1999 Aug;73(2):758-69.

Drouet B, Pinçon-Raymond M, Chambaz J, Pillot T. Laminin 1 attenuates beta-amyloid peptide Abeta(1-40) neurotoxicity of cultured fetal rat cortical neurons. J. Neurochem. 1999 Aug;73(2):742-9.

Pillot T, Goethals M, Najib J, Labeur C, Lins L, Chambaz J, Brasseur R, Vandekerckhove J, Rosseneu M. Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. J. Neurochem. 1999 Jan;72(1):230-7.

Pillot T, Lins L, Goethals M, Vanloo B, Baert J, Vandekerckhove J, Rosseneu M, Brasseur R. The 118-135 peptide of the human prion protein forms amyloid fibrils and induces liposome fusion. J. Mol. Biol. 1997 Dec 5;274(3):381-93.

Brasseur R, Pillot T, Lins L, Vandekerckhove J, Rosseneu M. Peptides in membranes: tipping the balance of membrane stability. Trends Biochem. Sci. 1997 May;22(5):167-71.

Pillot T, Goethals M, Vanloo B, Lins L, Brasseur R, Vandekerckhove J, Rosseneu M. Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Eur J Biochem. 1997 Feb 1;243(3):650-9. PubMed PMID: 9057828.

Pillot T, Goethals M, Vanloo B, Talussot C, Brasseur R, Vandekerckhove J, Rosseneu M, Lins L. Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. J Biol Chem. 1996 Nov 15;271(46):28757-65. PubMed PMID: 8910517.

Bohnet K, Pillot T, Visvikis S, Sabolovic N, Siest G. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res. 1996 Jun;37(6):1316-24. PubMed PMID: 8808766.

Pillot T, Barbier A, Visvikis A, Lozac'h K, Rosseneu M, Vandekerckhove J, Siest G. Single-step purification of two functional human apolipoprotein E variants hyperexpressed in Escherichia coli. Protein ExprPurif. 1996 Jun;7(4):407-14. PubMed PMID: 8776760.